MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced the appointment of Brian Connelly as President and Chief Executive Officer. Brian brings to the position more than two decades of biopharmaceutical industry experience bridging business and law. He succeeds Albert R. Collinson, Ph.D., who is stepping down as CEO after leading the company from phase 1 clinical studies to an FDA approval and commercial launch of Brenzavvy™ (bexagliflozin).
“Leading TheracosBio, building the great team that is in place now, bringing an affordable SGLT2 inhibitor to market and realizing the vision to reduce cost barriers and expand access to new medications for people with common diseases has been a great privilege,” said Dr. Collinson. “I am confident that Brian’s background and familiarity with the company’s story make him a great choice to lead the company into this next phase of growth, and I look forward to witnessing the team’s continued evolution and success.”
“Reaching the significant milestones of FDA approval of Brenzavvy and recent commercial launch with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) underscores TheracosBio’s compelling momentum in delivering cost-effective novel medications for conditions that impact millions of people,” said Connelly. “I am excited to be a part of the TheracosBio team as we continue to build upon all that has been achieved under Al’s leadership, and I am grateful that Al will continue to share his insights and experience as an advisor to the company.”
During his career, Brian has served in both advisory and managerial capacities in private and public life sciences companies. He practiced law for over 15 years with Faber, Daeufer & Itrato PC, a boutique law firm supporting the needs of biotech and life science companies, and has assisted early-stage drug development companies with CMC and supply chain matters, quality management systems and laboratory space planning. In 2017, he co-founded IncreVet, Inc., an innovative veterinary drug development company that gained FDA approval for an oral medication that was the first non-insulin treatment approved for the management of feline diabetes. IncreVet was acquired by Theracos, Inc., the parent company of TheracosBio, in early 2022. Mr. Connelly is a graduate of Boston College and the George Washington University Law School.
About TheracosBio
TheracosBio develops novel therapeutics for diseases with significant societal impact. The mission of TheracosBio is to expand access to new medications for patients with common diseases.
